Pharmaceuticals

Skyline Therapeutics Brings Multiple Data Presentations to ASGCT 2023

SHANGHAI, May 17, 2023 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company dedicated to developing unique and novel solutions to address unmet needs in rare and severe diseases, is showcasing multiple data presentations at the American Society of Gene and Cell Therapy ...

2023-05-17 18:00 1856

Fresh2 Reports Fiscal Year 2022 Annual Financial Results

NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ: ANPC), a company with operations inthe United States and China focused on early cancer screening and detection and entering into the operation of a ...

2023-05-17 04:15 2417

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

* WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody. * InflaRx received emergency use authorization (EUA) from the FDA for Gohibic (vilobelimab) for the treatment of certain critically ill COVID-19 patients in April ...

2023-05-16 16:00 1803

LG Chem Targets Sixfold Sales Growth in Battery Materials to KRW 30 Trillion by 2030

- Will expand sales portion in battery materials, sustainability business and innovative new drugs - Aims to accelerate in reaching net zero by 2050 by proactively building an integrated low-carbon management system SEOUL, South Korea, May 15, 2023 /PRNewswire/ -- LG Chem today announced i...

2023-05-16 09:34 2459

CMUH Smart Medicine System Assisted the ARDS Specialist Team Successfully Reversed the Patient's Critical Condition

TAICHUNG,Taiwan, May 15, 2023 /PRNewswire/ -- After the worldwide COVID-19 pandemic, most people suffered from mild disease, and "Acute Respiratory Distress Syndrome (ARDS)" is common for those critical COVID-19 patients. The 46-year-old of Ms. Chang, who had hypertension and nephropathy, accepte...

2023-05-15 20:30 1513

Gracell Biotechnologies Initiates Investigational Study Evaluating GC012F for Treatment of Refractory Systemic Lupus Erythematosus (SLE)

Gracell announces start of investigator-initiated trial to expand clinical evaluation of FasTCAR-T GC012F into autoimmune disease GC012F pioneers the use of CD19/BCMA dual-targeting CAR-T in SLE, aiming for deeper and wider depletion of autoantibodies producing B-cells and plasma cells SAN DIEGO...

2023-05-15 19:00 1726

LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate

SHANGHAI, May 12, 2023 /PRNewswire/ -- LaNova Medicines Ltd. ("LaNova Medicines") announced today it has entered into an exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), for LM-305, a pre-clinical stage antibody drug conjugate (ADC) targeting G protein-coupled receptor, class C...

2023-05-12 23:30 3880

Crystal Formulation Services' GMP Manufacturing Facility Successfully Passes the Remote Audit by US Client, Marking a Key Milestone for Its International Expansion

SUZHOU, China, May 12, 2023 /PRNewswire/ -- Today, Crystal Pharmatech announced that the GMP manufacturing facility of their CDMO business unit – Crystal Formulation Services (CFS) has successfully passed a remote audit conducted by a US client. The audit, which lasted for four days, confirmed th...

2023-05-12 21:00 2108

Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US

SUZHOU, China, May 11, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the Phase II clinical trial of in-house developed KX-826 for the treatm...

2023-05-11 23:30 2192

Fosun Pharma Participates in BEYOND Expo 2023 to Showcase Its Innovative R&D Achievements

MACAU, May 10, 2023 /PRNewswire/ -- From May 10 to 12, 2023, the 3rd BEYOND International Technology Innovation Expo — also known as BEYOND Expo 2023is being held at the Venetian Macau Convention and Exhibition Center. This year is the third consecutive year that Fosun Pharma (stock code: 600196....

2023-05-10 22:57 2658

CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology

SINGAPORE, May 9, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (Nasdaq: GDTC) ("CytoMed" or the "Company"), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, today ...

2023-05-09 22:07 2341

PharmAbcine to participate in "BIO International Convention 2023"

DAEJEON, South Korea, May 8, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of fully human antibody therapeutics, announced today that the company will participate in the upcoming BIO International Convention 2023. Details...

2023-05-08 20:00 1800

Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China

HANGZHOU, China, May 8, 2023 /PRNewswire/ -- Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply agreements to provide INBRIJA® in Greater China (Mainland China, Taiwan, Hong Kong, and Macao). INBRIJA is indicated in the United ...

2023-05-08 19:30 1483

Neuro3 Therapeutics Acquires Exclusive Worldwide Rights to Develop and Commercialize Clinical Stage KCNQ2 Activators from Lundbeck

CAMBRIDGE, Mass. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Neuro3 Therapeutics (Neuro3), a biotechnology company focused on the discovery and development of innovative medicines for the treatment of central nervous system (CNS) diseases, announced today the signing of an exclusive, worldwide...

2023-05-08 14:00 1534

BLISS BIOPHARMACEUTICAL ENTERS INTO A CLINICAL TRIAL COLLABORATION AGREEMENT WITH AN OPTION OF STRATEGIC COLLABORATION WITH EISAI FOR BB-1701

HANGZHOU, China, May 7, 2023 /PRNewswire/ -- Bliss Biopharmaceutical (Hangzhou) Co., Ltd, ("BlissBio") a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced a clinical trial collaboration agreement with option for strategic coll...

2023-05-08 07:00 2084

NEW THERAPY FOR RARE GASTROINTESTINAL STROMAL TUMOURS APPROVED IN SINGAPORE

* Singapore's Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatment of patients with 4th line GIST * QINLOCK significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in theINVICTUS Phase 3 Study1,2 ...

2023-05-08 04:00 1811

Suzhou GenAssist Therapeutic Co.,Ltd recently announced that its first base editing product, GEN6050, has submitted a pre-IND application to the FDA and has been accepted

SUZHOU, China, May 6, 2023 /PRNewswire/ -- Suzhou GenAssist Therapeutic Co.,Ltd recently announced its pre-IND application of their first base editing product, GEN6050 and the acceptance by the FDA.   GEN6050 is an in vivo base editing drug that targets exon 50 skipping in the Duchenne muscular...

2023-05-06 21:00 4600

Empowering Innovation to the Global Market with Acro Certify

NEWARK, Del., May 5, 2023 /PRNewswire/ -- For many companies, entering the global market is a daunting challenge. These obstacles can come in various forms. Sometimes the problem is finding the right target customer base or establishing an appropriate quality management system and shipping logist...

2023-05-06 10:18 4748

CARsgen's CLDN18.2 mAb AB011 Achieves IND Clearance from the NMPA for the First-line Combination Treatment of Gastric Cancer

SHANGHAI, May 5, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that AB011 in combination with atezolizumab monoclonal antibody, Roche'...

2023-05-05 20:50 3155

ProQure and Identiv Partner to Launch Innovative NFC Type 2 Tags for Large-Scale NFC Deployments

The partnership's new PQ201/201s series tags deliver premium features at a competitive price point PLEASANTON, Calif., May 5, 2023 /PRNewswire/ -- ProQure, a technology provider of IoT cloud management for physical objects, and Identiv, a global leader in physical security and secure identificat...

2023-05-05 18:00 2256
1 ... 30313233343536 ... 113